Lyell Immunopharma, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Lyell Immunopharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2020 to Q3 2024.
  • Lyell Immunopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $7.62M, a 27.5% decline year-over-year.
  • Lyell Immunopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $33.5M, a 41.2% decline year-over-year.
  • Lyell Immunopharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $47.1M, a 42.5% decline from 2022.
  • Lyell Immunopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $81.9M, a 31.7% increase from 2021.
  • Lyell Immunopharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $62.2M, a 87% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $33.5M $7.62M -$2.89M -27.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $36.4M $8.28M -$5.94M -41.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $42.4M $9.16M -$4.73M -34.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $47.1M $8.46M -$9.9M -53.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $57M $10.5M -$8.61M -45% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $65.6M $14.2M -$8.19M -36.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $73.8M $13.9M -$8.15M -37% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $81.9M $18.4M -$2.82M -13.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $84.7M $19.1M +$6.08M +46.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $78.7M $22.4M +$7.16M +47% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $71.5M $22M +$9.3M +73% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $62.2M $21.2M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $13M +$3.29M +33.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $15.2M +$7.98M +110% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $12.7M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q3 2020 $9.75M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $7.27M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.